Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IntraMEMS

Financiado

Microfluidic platform for intra operative tumor immunohistochemistry

We propose to develop an automated microfluidic platform for rapid analysis of the margins of frozen resections of tumors. It will allow cancer cells to be specifically distinguished from healthy cells during the time course of th... ver más

30/11/2016

EPFL

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-11-30

ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

2 Participantes

EPFL

150.00K€ | Lider

REPSOL / GALP

233.16K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-094494-B-C22 DISEÑO DE HERRAMIENTAS DE MICROSCOPIA TRIDIMENSIONAL Y PROCE... 129K€ Cerrado

BIO2011-30535-C04-03 SEPARACION ACUSTICA DE CELULAS TUMORALES EN SANGRE CON CHIPS... 80K€ Cerrado

PID2020-120306RB-I00 INTEGRAL STAGING, PROGNOSTIC AND DIAGNOSTIC OF CANCER IN LIQ... 184K€ Cerrado

BIO2011-30535-C04-01 DESARROLLO DE TECNOLOGIA ULTRASONICA DE ALTO RENDIMIENTO PAR... 121K€ Cerrado

STAIN-IT Non-invasive computational immunohistochemical staining base... 2M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-05-18
Fecha Fin: 2016-11-30

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto We propose to develop an automated microfluidic platform for rapid analysis of the margins of frozen resections of tumors. It will allow cancer cells to be specifically distinguished from healthy cells during the time course of the surgical intervention itself via an immunohistochemistry (IHC) staining protocol completed in 5 minutes. The interest of such platform is that late-positivity, which is defined as the detection of cancer cells within the resection margin of the tumor by means of classical IHC after surgery, can be reduced or even avoided. Patients diagnosed with latepositive margins carry a high risk of cancer recurrence due to possible tumor cells left in the body. Intra-operative margin assessment of tumor resections is already done to evaluate the presence of such remaining cancer cells using different techniques. The most common one is microscopic morphological examination by applying hematoxylin and eosin (H&E) staining on cryo-sectioned surgical specimens, because it can be done easily in a matter of minutes. However, the major drawback of this method is the lack of cancer cell-specific staining: the interpretation relies only on morphology and small numbers of cancer cells infiltrating into healthy tissue are not easily recognizable. We therefore will develop a platform that can perform IHC together with H&E staining on cryo-sectioned samples within 5 minutes. Combining IHC that targets cancer cell-specific proteins with H&E staining will show unequivocally the presence of cancer cells and minimize those variations in the outcome of the analysis that originate from the pathologist’s personal interpretation. It will potentially decrease the recurrence rate, increase the success of post-operative treatment, and reduce unnecessary surgical rescissions.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores